The Experts below are selected from a list of 10785 Experts worldwide ranked by ideXlab platform
Paul T Finger - One of the best experts on this subject based on the ideXlab platform.
-
doctor reported outcomes real world data from a tertiary Eye Cancer center
Indian Journal of Ophthalmology, 2021Co-Authors: Abhilasha Maheshwari, Paul T Finger, Abhishek Malpani, Puneet Jain, Ankit Singh Tomar, Gaurav GargAbstract:Purpose To provide real-world data on the world-wide-web for patient and doctor awareness. Methods From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Each result was anonymized, entered in an online portal, and sent to a unique software program where it was used to create real-world data of number of patients, mean vision, local tumor control, Eye salvage, systemic metastases, and length of follow-up for our Eye Cancer center. Results A HIPAA compliant, internet-based software program was developed and linked to public access web page to collect and analyze near-real-time data pertaining to the treatment, vision, life, and follow-up time of patients. During this period, CM radiation plaque tumor control was 99.7%, median vision 20/25 (mean 20/50) and Eye salvage 95.8%. ICM tumor control was 99.1% and the median vision 20/20 (mean 20/20). OSSC tumor control was 100% and the most common vision was 20/20 (mean 20/25). Rates of primary enucleation as treatment were 4.2% for CM, 2.8% for ICM, and 0% for OSSC. All patient results were updated by the ophthalmic oncology fellow at each patient visit as to reflect near-real-time outcomes at our center. Conclusion Prospective data collection of returning patients was found to be a simple method to reflect patient care outcomes. This method of reporting doctor outcomes offers a measure of transparency for patients and an opportunity to compare results with other clinical practices.
-
multicenter international assessment of the eighth edition of the american joint committee on Cancer Cancer staging manual for conjunctival melanoma
JAMA Ophthalmology, 2019Co-Authors: Puneet Jain, Paul T Finger, Sarah E Coupland, Bertil Damato, Heinrich Heimann, N Kenawy, Niels J Brouwer, Marina Marinkovic, Jeanpierre Caujolle, Celia MaschiAbstract:Importance Eye Cancer staging systems used for standardizing patient care and research need to be validated. Objective To evaluate the accuracy of the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual in estimating metastatis and mortality rates of conjunctival melanoma. Design, Setting, and Participants This international, multicenter, registry-based case series pooled data from 10 ophthalmic oncology centers from 9 countries on 4 continents. A total of 288 patients diagnosed with conjunctival melanoma from January 1, 2001, to December 31, 2013, were studied. Data analysis was performed from July 7, 2018, to September 11, 2018. Interventions Treatments included excision biopsy, cryotherapy, topical chemotherapy, radiation therapy, enucleation, and exenteration. Main Outcomes and Measures Metastasis rates and 5-year and 10-year Kaplan-Meier mortality rates according to the clinical T categories and subcategories of the eighth edition of the AJCC Cancer Staging Manual. Results A total of 288 Eyes from 288 patients (mean [SD] age, 59.7 [16.8] years; 147 [51.0%] male) with conjunctival melanoma were studied. Clinical primary tumors (cT) were staged at presentation as cT1 in 218 patients (75.7%), cT2 in 34 (11.8%), cT3 in 15 (5.2%), and cTx in 21 (7.3%). There were no T4 tumors. Pathological T categories (pT) were pTis in 43 patients (14.9%), pT1 in 169 (58.7%), pT2 in 33 (11.5%), pT3 in 12 (4.2%), and pTx in 31 (10.8%). Metastasis at presentation was seen in 5 patients (1.7%). Metastasis during follow-up developed in 24 patients (8.5%) after a median time of 4.3 years (interquartile range, 2.9-6.0 years). Of the 288 patients, 29 died (melanoma-related mortality, 10.1%) at a median time of 5.3 years (interquartile range, 1.8-7.0 years). The cumulative rates of mortality among patients with cT1 tumors were 0% at 1 year, 2.5% (95% CI, 0.7%-7.7%) at 5 years, and 15.2% (95% CI, 8.1%-27.4%) at 10 years of follow-up; among patients with cT2 tumors, 0% at 1 year, 28.6% (95% CI, 12.9%-58.4%) at 5 years, and 43.6% (95% CI, 19.6%-77.9%) at 10 years of follow-up; and among patients with cT3 tumors, 21.1% (95% CI, 8.1%-52.7%) at 1 year of follow-up and 31.6% (95% CI, 13.5%-64.9%) at 5 years of follow-up. Patients with cT2 and cT3 tumors had a significantly higher cumulative mortality rate compared with those presenting with cT1 tumors (log-rank P < .001). Patients with ulcerated melanomas had significantly higher risk of mortality (hazard ratio, 7.58; 95% CI, 1.02-56.32; P = .04). Conclusions and Relevance This multicenter, international, collaborative study yielded evidence that the conjunctival melanoma staging system in the eighth edition of the AJCC Cancer Staging Manual can be used to accurately estimate metastasis and mortality rates. These findings appear to support the use of AJCC staging as a tool for patient care and research.
-
orbital lymphoma an international multicenter retrospective study
American Journal of Ophthalmology, 2019Co-Authors: Tine Gadegaard Olsen, Frederik Holm, Lauge Hjorth Mikkelsen, Peter Kristian Rasmussen, Paul T Finger, Sarah E Coupland, Hans E Grossniklaus, Gregory F Graue, Bita Esmaeli, Santosh G HonavarAbstract:Purpose To investigate and characterize the clinical features of subtype-specific orbital lymphoma. Design Retrospective, interventional case series. Methods The study included 7 international Eye Cancer centers. Patient data were collected from January 1, 1980 through December 31, 2017. A total of 797 patients with a histologically verified orbital lymphoma were included. The primary endpoints were overall survival, disease-specific survival, and progression-free survival. Results The median age was 64 years, and 51% of patients (n = 407) were male. The majority of lymphomas were of B-cell origin (98%, n = 779). Extranodal marginal zone B-cell lymphoma (EMZL) was the most frequent subtype (57%, n = 452), followed by diffuse large B-cell lymphoma (DLBCL) (15%, n = 118), follicular lymphoma (FL) (11%, n = 91), and mantle cell lymphoma (MCL) (8%, n = 66). Localized Ann Arbor stage IE EMZL and FL were frequently treated with external beam radiation therapy. DLBCL, MCL, and disseminated EMZL and FL were primarily treated with chemotherapy. EMZL and FL patients had a markedly better prognosis (10-year disease-specific survival of 92% and 71%, respectively) than DLBCL and MCL patients (10-year disease-specific survival of 41% and 32%, respectively). Conclusions Four lymphoma subtypes were primarily found in patients with orbital lymphoma: EMZL, DLBCL, FL, and MCL. The histologic subtype was found to be the main predictor for outcome, with EMZL and FL patients having a markedly better prognosis than DLBCL and MCL.
-
conjunctival lymphoma an international multicenter retrospective study
JAMA Ophthalmology, 2016Co-Authors: Marina M Kirkegaard, Peter Kristian Rasmussen, Paul T Finger, Santosh G Honavar, Sarah E Coupland, Hans E Grossniklaus, Gregory F Graue, Bita Esmaeli, Jwu Jin Khong, Penny MckelvieAbstract:Importance To date, the clinical features of the various subtypes of conjunctival lymphoma (CL) have not been previously evaluated in a large cohort. Objective To characterize subtype-specific clinical features of CL and their effect on patient outcome. Design, Setting, and Participants A retrospective multicenter study was performed. Patient data were collected from January 1, 1980, through December 31, 2010. The dates of the analysis were May 15, 2015, to August 20, 2015. The median follow-up period was 43 months. Seven Eye Cancer centers were involved in the study. In total, 268 patients with CL were identified, 5 of whom were excluded because of missing clinical data. Main Outcomes and Measures Overall survival, disease-specific survival, and progression-free survival were the primary end points. Results Two hundred sixty-three patients with CL were included in the study. Their mean age was 61.3 years, and 55.1% (145 of 263) were female. All lymphomas were of B-cell type. The most frequent subtype was extranodal marginal zone lymphoma (EMZL) (68.4% [180 of 263]), followed by follicular lymphoma (FL) (16.3% [43 of 263]), mantle cell lymphoma (MCL) (6.8% [18 of 263]), and diffuse large B-cell lymphoma (DLBCL) (4.6% [12 of 263). Conjunctival lymphoma commonly manifested in elderly individuals (age range, 60-70 years old), with EMZL having a female predilection (57.8% [104 of 180]) and MCL having a marked male predominance (77.8% [14 of 18]). Unlike EMZL and FL, DLBCL and MCL were frequently secondary diseases (41.7% [5 of 12] and 88.9% [16 of 18], respectively), with MCL showing a frequent occurrence of stage IVE lymphoma (61.1% [11 of 18]) and bilateral manifestation (77.8% [14 of 18]). Localized disease (stage IE or IIE) was commonly treated with external beam radiation therapy (EBRT) with or without chemotherapy, while widespread lymphoma (stage IIIE or IVE) and MCL of any stage were managed with chemotherapy with or without EBRT. Diffuse large B-cell lymphoma and MCL had a poor prognosis, with 5-year disease-specific survival of 55.0% and 9.0%, respectively, in contrast to EMZL (97.0%) and FL (82.0%). Further survival predictors included age (EMZL), sex (FL), and Ann Arbor staging classification (EMZL and FL). The American Joint Committee on Cancer TNM staging showed limited prognostic usefulness, only being able to predict survival for patients with DLBCL. Conclusions and Relevance Conjunctival lymphoma consists of mainly 4 subtypes of B-cell non-Hodgkin lymphoma: EMZL, FL, MCL, and DLBCL. Mantle cell lymphoma is characterized by a particularly high frequency of secondary disease of stage IVE and bilateral manifestation. The histological subtype is the main outcome predictor, with MCL and DLBCL having a markedly poorer prognosis than EMZL and FL.
-
international validation of the american joint committee on Cancer s 7th edition classification of uveal melanoma
JAMA Ophthalmology, 2015Co-Authors: Rand E Simpson, Paul T Finger, Brenda L Gallie, Matthew W Wilson, S V Saakyan, Anush Amiryan, Kimberly J Chin, Stefan Seregard, Maria Fili, Barrett G HaikAbstract:Importance Although an accurate uveal melanoma staging system is needed to improve research and patient care, the evaluation of Eye Cancer staging systems requires international multicenter data sharing to acquire a statistically significant analysis. Objective To assess patient mortality outcomes associated with uveal melanoma staging according to the 7th edition of the American Joint Committee on Cancer’sAJCC Cancer Staging Manual. Design, Setting, Participants A committee was formed to create patient-specific data fields for patients with uveal melanoma. Ten subspecialty ophthalmic oncology centers from 4 continents shared data. Patient selection criteria included diagnosis of uveal melanoma from April 1, 2001, to April 1, 2011, adequate records to allow tumor staging by the AJCC criteria, and follow-up for metastatic melanoma. Interventions Primary treatments included local resection, radiation therapy, and enucleation. Main Outcomes and Measures Metastasis after initial tumor staging with 5- and 10-year Kaplan-Meier metastasis-free point estimates, depending on AJCC prognostic stages I through IV, tumor size category, and subclassification (defined by the presence of ciliary body involvement and/or extrascleral extension). Results A total of 3809 patients were entered into the database. Of these, 3377 records (88.7%) were complete. Primary ciliary body and choroidal melanoma was the diagnosis for 3217, and 160 had primary iris melanoma. Tumor size categories were T1 in 1115 (34.7%) of the 3217 patients, T2 in 1128 patients (35.1%), T3 in 789 patients (24.5%), and T4 in 185 patients (5.8%). The 5- and 10-year Kaplan-Meier metastasis-free point estimates by tumor size categories were 97% (95% CI, 95%-98%) and 94% (95% CI, 91%-96%) for T1 tumors, 85% (95% CI, 82%-88%) and 80% (95% CI, 75%-84%) for T2 tumors, 77% (95% CI, 73%-80%) and 68% (95% CI, 60%-74%) for T3 tumors, and 61% (95% CI, 49%-71%) (5-year only) for T4 tumors, respectively. Increasing tumor size was consistent with increased metastasis risk (P Conclusions and Relevance Multicenter, worldwide, Internet-based data sharing was used to study a heterogenous patient population in ophthalmic oncology. Our results support the continued use of the 7th edition of theAJCCCancer Staging Manual for uveal melanoma.
Bassem A Hassan - One of the best experts on this subject based on the ideXlab platform.
-
the ccr4 not complex is a tumor suppressor in drosophila melanogaster Eye Cancer models
Journal of Hematology & Oncology, 2018Co-Authors: Carmen Vicente, Rocco Stirparo, Sofie Demeyer, Charles E De Bock, Olga Gielen, Mardelle Atkins, Jiekun Yan, Georg Halder, Bassem A HassanAbstract:The CNOT3 protein is a subunit of the CCR4-NOT complex, which is involved in mRNA degradation. We recently identified CNOT3 loss-of-function mutations in patients with T-cell acute lymphoblastic leukemia (T-ALL). Here, we use different Drosophila melanogaster Eye Cancer models to study the potential tumor suppressor function of Not3, the CNOT3 orthologue, and other members of the CCR4-NOT complex. Our data show that knockdown of Not3, the structural components Not1/Not2, and the deadenylases twin/Pop2 all result in increased tumor formation. In addition, overexpression of Not3 could reduce tumor formation. Not3 downregulation has a mild but broad effect on gene expression and leads to increased levels of genes involved in DNA replication and ribosome biogenesis. CycB upregulation also contributes to the Not3 tumor phenotype. Similar findings were obtained in human T-ALL cell lines, pointing out the conserved function of Not3. Together, our data establish a critical role for Not3 and the entire CCR4-NOT complex as tumor suppressor.
-
the ccr4 not complex is a tumor suppressor in drosophila melanogaster Eye Cancer models
Journal of Hematology & Oncology, 2018Co-Authors: Carmen Vicente, Rocco Stirparo, Sofie Demeyer, Charles E De Bock, Olga Gielen, Mardelle Atkins, Jiekun Yan, Georg Halder, Bassem A HassanAbstract:Background The CNOT3 protein is a subunit of the CCR4-NOT complex, which is involved in mRNA degradation. We recently identified CNOT3 loss-of-function mutations in patients with T-cell acute lymphoblastic leukemia (T-ALL).
Barrett G Haik - One of the best experts on this subject based on the ideXlab platform.
-
international validation of the american joint committee on Cancer s 7th edition classification of uveal melanoma
JAMA Ophthalmology, 2015Co-Authors: Rand E Simpson, Paul T Finger, Brenda L Gallie, Matthew W Wilson, S V Saakyan, Anush Amiryan, Kimberly J Chin, Stefan Seregard, Maria Fili, Barrett G HaikAbstract:Importance Although an accurate uveal melanoma staging system is needed to improve research and patient care, the evaluation of Eye Cancer staging systems requires international multicenter data sharing to acquire a statistically significant analysis. Objective To assess patient mortality outcomes associated with uveal melanoma staging according to the 7th edition of the American Joint Committee on Cancer’sAJCC Cancer Staging Manual. Design, Setting, Participants A committee was formed to create patient-specific data fields for patients with uveal melanoma. Ten subspecialty ophthalmic oncology centers from 4 continents shared data. Patient selection criteria included diagnosis of uveal melanoma from April 1, 2001, to April 1, 2011, adequate records to allow tumor staging by the AJCC criteria, and follow-up for metastatic melanoma. Interventions Primary treatments included local resection, radiation therapy, and enucleation. Main Outcomes and Measures Metastasis after initial tumor staging with 5- and 10-year Kaplan-Meier metastasis-free point estimates, depending on AJCC prognostic stages I through IV, tumor size category, and subclassification (defined by the presence of ciliary body involvement and/or extrascleral extension). Results A total of 3809 patients were entered into the database. Of these, 3377 records (88.7%) were complete. Primary ciliary body and choroidal melanoma was the diagnosis for 3217, and 160 had primary iris melanoma. Tumor size categories were T1 in 1115 (34.7%) of the 3217 patients, T2 in 1128 patients (35.1%), T3 in 789 patients (24.5%), and T4 in 185 patients (5.8%). The 5- and 10-year Kaplan-Meier metastasis-free point estimates by tumor size categories were 97% (95% CI, 95%-98%) and 94% (95% CI, 91%-96%) for T1 tumors, 85% (95% CI, 82%-88%) and 80% (95% CI, 75%-84%) for T2 tumors, 77% (95% CI, 73%-80%) and 68% (95% CI, 60%-74%) for T3 tumors, and 61% (95% CI, 49%-71%) (5-year only) for T4 tumors, respectively. Increasing tumor size was consistent with increased metastasis risk (P Conclusions and Relevance Multicenter, worldwide, Internet-based data sharing was used to study a heterogenous patient population in ophthalmic oncology. Our results support the continued use of the 7th edition of theAJCCCancer Staging Manual for uveal melanoma.
-
chemotherapy for Eye Cancer
Survey of Ophthalmology, 2001Co-Authors: Matthew W Wilson, Paul T Finger, Grazyna Czechonska, Aaron R Rausen, Mary E Hooper, Barrett G HaikAbstract:Chemotherapy has been used to treat a multitude of Eye Cancers. We attempted to review the role of chemotherapy in the treatment of ocular, adnexal, and orbital malignancies by conducting an extensive search of the medical literature. Unfortunately, the published reports typically contain few patients with limited follow-up, precluding definitive recommendations. For most Eye Cancers, multicenter trials will offer the potential to gather the numbers of patients required to determine the clinical utility of chemotherapy.
Carol L Shields - One of the best experts on this subject based on the ideXlab platform.
-
Eye Cancer in a young male with a vaping history
Indian Journal of Ophthalmology, 2020Co-Authors: Carol L Shields, Min Kim, Sara E Lally, Patricia Chevezbarrios, Jerry A ShieldsAbstract:We report a new observation of conjunctival intraepithelial neoplasia (CIN) in a young man following years of electronic cigarette use. A 22-year-old man with a 5-year electronic cigarette use (vaping) developed painless unilateral blurred vision in the right Eye from mild superficial corneal opacification, unresponsive to topical antiviral therapy. Corneal scraping documented no infectious etiology. The abnormality persisted for 1 year and superficial keratectomy revealed high-grade CIN with enlarged pleomorphic and dyskeratotic cells. Interferon-alpha-2b was instituted. In this case, chronic exposure to electronic cigarette vapors (vaping) could have been associated with CIN in this young patient.
-
the middle meningeal artery as an alternative route for intra arterial chemotherapy
Interdisciplinary Neurosurgery, 2015Co-Authors: Mario Zanaty, Nohra Chalouhi, Carol L Shields, Stavropoula Tjoumakaris, Robert H Rosenwasser, Pascal JabbourAbstract:Abstract Retinoblastoma is a deadly Eye Cancer in children, leading to death in 50%–70% of children in undeveloped nations. Unfortunately, this aggressive tumor is the most common intraocular malignancy worldwide. For the last 2 decades, intravenous (IV) chemotherapy has been the mainstay of treatment for retinoblastomas. This route has provided improved control in retinoblastoma, with sparing of the Eye and vision in some cases. More recently, intra-arterial chemotherapy (IAC) has become the first line treatment for advanced and refractory retinoblastoma in many centers worldwide. The advances in treatment along with early tumor detection are responsible for the favorable prognosis found in developed nations. IAC classically uses the ophthalmic artery (OA) in attempt to deliver the maximal dose of chemotherapy while minimizing systemic complications. However, direct catheterization of the ophthalmic artery (OA) is not always possible. The purpose of this article is to describe a case where the OA has been thrombosed and an alternative access route using the middle meningeal artery (MMA) was used.
-
Cancer and the Eye giant steps forward the cambridge symposium 2012
Eye, 2013Co-Authors: Jerry A Shields, Carol L ShieldsAbstract:The Cambridge Ophthalmological Symposium was conceived as a 2-day intense meeting for the in-depth study of specific fields of Eye disease. This noble conference, held on the grounds of St John's College in the campus of Cambridge University rings with character, educational giants, footsteps of previous Nobel Prize winners, and a taste of early autumn. The symposium began in 1971 with ‘Glaucoma', headed by Professor Hans Goldman, and meandered into other topics of ‘Connective Tissue Disease of the Eye' in 1974 guided by Dr Edward Maumenee and ‘The Optic Nerve' in 1976 lead by Dr William Hoyt. It was 1977 when the first study of Eye Cancer was undertaken in a formal fashion by this esteemed symposium entitled ‘Pigmented Tumours' and directed by Dr Frederick Blodi. At that time, the field of ocular oncology was in its infancy. The challenge was simple. The task was to find clinical features that typified the main intraocular tumors, namely nevus, melanoma, metastasis, and retinoblastoma. Fluorescein angiography and ultrasonography were in early development as ocular imaging techniques, potentially able to detect a mass within the Eye. The radioactive phosphorus (P32) uptake test was the in-fashion method to confirm malignancy. At that time, an Eye with either uveal melanoma or retinoblastoma was usually removed and techniques of laser and irradiation were being explored. With regard to uveal melanoma, a heated controversy was eminent, with proponents of observation for small melanomas versus others demanding immediate enucleation for such lesions. The challenge was simple. The prognosis was ominous. Fast forward to 35 years later. The topic of Eye Cancer was revisited in 2012 at the Cambridge Ophthalmological Symposium under the title of ‘Cancer and the Eye' and coordinated by Professor Bertil Damato of Liverpool, England. Huge advances have been made in this three-decade intermission.1, 2 Not only have we refined ultrasonography and fluorescein angiography but we have developed other methods for ocular imaging including magnetic resonance imaging for large tumors and extremely powerful imaging of sub-millimeter tumors, down to a few microns, with enhanced depth image optical coherence tomography (EDI-OCT). Believe it or not, we can now measure choroidal tumors in their infancy, using EDI-OCT, before they are clinically visible. The P32 test, although highly reliable in differentiating benign from malignant tumors, has been abandoned because fine needle aspiration biopsy has been introduced and perfected. Ocular oncologists have become quite proficient in recognizing intraocular tumors with slit lamp biomicroscopy, binocular indirect ophthalmoscopy, and other non-invasive methods. And there's more. With regard to retinoblastoma, the genetics of this malignancy have since been defined and we can predict at-risk family members. We have incredible new techniques involving delivery of chemotherapy into the vein, the artery, the subTenon's space, and even into the vitreous to provide tumor control, save the Eye, and often provide remarkable visual outcome. Enucleation, once the most common method of treating retinoblastoma, is performed much less often and the great majority of Eyes are salvaged today. With regard to melanoma, the past three decades have seen a revolution in conservative therapy with early detection of melanoma when the tumor is 1–2 mm in thickness rather than previously 8–10 mm. We have a better understanding of the differences between the benign choroidal nevus and malignant melanoma, using published risk factors for tumor growth and metastasis, and we currently are exploring the molecular pathways for the development of melanoma. Since 1977, there have been newly defined intraocular tumors that were not widely recognized in the past. These include choroidal osteoma, uveal melanocytoma, leiomyoma, schwannoma, iris lacrimal gland choristoma, retinal lymphoma, retinocytoma, vasoproliferative tumor, combined hamartoma of the retina and retinal pigment epithelium (RPE), pigmented ocular fundus lesions with familial adenomatous polyposis, and others. Moreover, we have clarified the differentiation of the various pigmented tumors of the Eye from congenital hypertrophy of the RPE to adenoma of the RPE to pigmented medulloepithelioma to choroidal nevus to choroidal melanoma and even to the ‘rare birds' of congenital simple RPE hamartoma, torpedo maculopathy, and others. Looking back, out of breath, we have taken giant steps in defining tumors of the Eye. At the 2012 symposium, there were fascinating discussions on subjects not foreseen in the 1977 meeting, including the hallmarks of Cancer, the molecular biology of retinoblastoma, melanoma, and lymphoma, and the immunology of Cancers. Discussion of new therapies using techniques of tumor resection, lasers, photodynamic therapy, and methods of radiotherapy with plaque brachytherapy, charged particles, gamma knife, and robotic cyberknife methods. Diagnostic fine needle biopsy indications, techniques, and results were deliberated. There were overviews on the current state-of-the-art of management of retinoblastoma, lymphoma, melanoma, metastasis, and vascular tumors. Huge strides in the innovative chemotherapy methods for retinoblastoma have culminated in the highest cure rate for any pediatric malignancy. Children with retinoblastoma can expect complete eradication of the malignancy with low risk for recurrence and with the added benefit of globe salvage and decent visual acuity in most cases. Novel methods of genetically typing uveal melanoma into low-risk or high-risk tumors using DNA or RNA methods have lead to a better understanding of melanoma behavior and hopefully future targeted therapy. And there's even more. The field of ocular oncology has matured into an esteemed and respected subspecialty of ophthalmology with centers of excellence in most developed nations. A recognized International Society of Ocular Oncology was established in 2006 and biennual meetings have had presentations of cutting edge ideas, investigations, genomics, and therapies. Ocular oncology is exploding with fast forward movement. One of us (JAS) participated in both the 1997 and the 2012 Cambridge symposia and has personally witnessed this incredibly rapid progress in the field of ocular oncology. So in 1977, we were taking baby steps in learning the task at hand—definition of the features of intraocular tumors. Now in 2012, we are beginning to take giant steps forward in understanding, trapping, and eliminating intraocular tumors before they threaten the patient. These giant steps will hopefully help to prolong life, preserve Eyes, and provide better vision for our patients.
-
pearls and pitfalls of intraarterial chemotherapy for retinoblastoma
Journal of Neurosurgery, 2012Co-Authors: Pascal Jabbour, Nohra Chalouhi, Stavropoula Tjoumakaris, Robert H Rosenwasser, Fernando L Gonzalez, Aaron S Dumont, Rohan Chitale, Carlos Bianciotto, Carol L ShieldsAbstract:Retinoblastoma is a deadly Eye Cancer in children, leading to death in 50%–70% of children in undeveloped nations who are diagnosed with it. This malignancy is the most common intraocular tumor in childhood worldwide. The good prognosis in developed nations is related to early detection and advanced treatments. With the advent of intraarterial chemotherapy, neurosurgeons have taken a central role in the treatment of this pediatric condition. Intraarterial chemotherapy is a novel treatment for retinoblastoma whereby chemotherapeutic agents are precisely delivered into the ophthalmic artery, minimizing systemic toxicity. This procedure has shown impressive results and has allowed a dramatic decrease in the rate of enucleation (Eye removal) in advanced and refractory retinoblastoma. Recent reports have raised some concerns about the risk of ocular vasculopathy, radiation-related toxicity, and the potential for metastatic disease after intraarterial chemotherapy. In the authors' experience of more than 3 year...
-
pearls and pitfalls of intraarterial chemotherapy for retinoblastoma
Journal of Neurosurgery, 2012Co-Authors: Pascal Jabbour, Nohra Chalouhi, Stavropoula Tjoumakaris, Robert H Rosenwasser, Fernando L Gonzalez, Aaron S Dumont, Rohan Chitale, Carlos Bianciotto, Carol L ShieldsAbstract:Retinoblastoma is a deadly Eye Cancer in children, leading to death in 50%-70% of children in undeveloped nations who are diagnosed with it. This malignancy is the most common intraocular tumor in childhood worldwide. The good prognosis in developed nations is related to early detection and advanced treatments. With the advent of intraarterial chemotherapy, neurosurgeons have taken a central role in the treatment of this pediatric condition. Intraarterial chemotherapy is a novel treatment for retinoblastoma whereby chemotherapeutic agents are precisely delivered into the ophthalmic artery, minimizing systemic toxicity. This procedure has shown impressive results and has allowed a dramatic decrease in the rate of enucleation (Eye removal) in advanced and refractory retinoblastoma. Recent reports have raised some concerns about the risk of ocular vasculopathy, radiation-related toxicity, and the potential for metastatic disease after intraarterial chemotherapy. In the authors' experience of more than 3 years, tumor control is excellent with globe salvage at 67% and vascular events less than 5%, mostly related to improvement in technique. The role of this novel approach in the management of retinoblastoma has yet to be defined. As more centers are adopting the technique, the topic will decidedly become the focus of intensive future research. In this paper, the authors review and discuss current data regarding intraarterial chemotherapy for retinoblastoma.
Carmen Vicente - One of the best experts on this subject based on the ideXlab platform.
-
the ccr4 not complex is a tumor suppressor in drosophila melanogaster Eye Cancer models
Journal of Hematology & Oncology, 2018Co-Authors: Carmen Vicente, Rocco Stirparo, Sofie Demeyer, Charles E De Bock, Olga Gielen, Mardelle Atkins, Jiekun Yan, Georg Halder, Bassem A HassanAbstract:The CNOT3 protein is a subunit of the CCR4-NOT complex, which is involved in mRNA degradation. We recently identified CNOT3 loss-of-function mutations in patients with T-cell acute lymphoblastic leukemia (T-ALL). Here, we use different Drosophila melanogaster Eye Cancer models to study the potential tumor suppressor function of Not3, the CNOT3 orthologue, and other members of the CCR4-NOT complex. Our data show that knockdown of Not3, the structural components Not1/Not2, and the deadenylases twin/Pop2 all result in increased tumor formation. In addition, overexpression of Not3 could reduce tumor formation. Not3 downregulation has a mild but broad effect on gene expression and leads to increased levels of genes involved in DNA replication and ribosome biogenesis. CycB upregulation also contributes to the Not3 tumor phenotype. Similar findings were obtained in human T-ALL cell lines, pointing out the conserved function of Not3. Together, our data establish a critical role for Not3 and the entire CCR4-NOT complex as tumor suppressor.
-
the ccr4 not complex is a tumor suppressor in drosophila melanogaster Eye Cancer models
Journal of Hematology & Oncology, 2018Co-Authors: Carmen Vicente, Rocco Stirparo, Sofie Demeyer, Charles E De Bock, Olga Gielen, Mardelle Atkins, Jiekun Yan, Georg Halder, Bassem A HassanAbstract:Background The CNOT3 protein is a subunit of the CCR4-NOT complex, which is involved in mRNA degradation. We recently identified CNOT3 loss-of-function mutations in patients with T-cell acute lymphoblastic leukemia (T-ALL).
-
Additional file 5: of The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster Eye Cancer models
2018Co-Authors: Carmen Vicente, Rocco Stirparo, Sofie Demeyer, Olga Gielen, Mardelle Atkins, Jiekun Yan, Georg Halder, Charles De Bock, Bassem Hassan, Jan CoolsAbstract:Figure S4. Stabilization of mRNA expression levels of Cycb, fancl, and upd2 upon Not3 downregulation and transcription inhibition on Drosophila S2 cells in vitro. A) Percentage of YFP expressing cells upon addition of CuSO4 on the cell media. B) Expression of the different genes at time-point 0. Our results show a clear knockdown of the Not3 mRNA expression (almost 50% efficiency) at time point 0 h, which was associated with upregulation of Cycb, fancl, and upd2. C) Cycb, fancl, and upd2 mRNAs showed a moderate increase in stability after Not3 downregulation when compared with the control condition (YFP expression). In all figure panels, results are shown as mean ± S.D. Three independent experiments were performed. (PDF 418 kb
